Letter to the EditorFirst report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases
Section snippets
Conflict of interest
There is no conflict of interest.
Acknowledgment
We would like to acknowledge the Mycology reference laboratory in Bristol from Public Health England for confirming the identification of the five C. auris isolates.
References (7)
- et al.
First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia
J Infect
(2016) - et al.
Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital
Microbiol Immunol
(2009) Candida auris in healthcare settings – Europe – 19 December 2016
(2016)
There are more references available in the full text version of this article.
Cited by (71)
Overview about Candida auris: What's up 12 years after its first description?
2022, Journal of Medical MycologyCandida auris: A new, threatening yeast
2021, Encyclopedia of MycologyCandida auris: Clinical profile, diagnostic challenge and susceptibility pattern: Experience from a tertiary-care centre in South India
2020, Journal of Global Antimicrobial ResistanceCitation Excerpt :However, only two patients (18%) were previously treated with fluconazole. This is in contrast to data from several parts of the globe that describe patients receiving antifungal therapy such as fluconazole prior to infection [20–22]. Table 4 depicts the current Indian status in the diagnosis, AFST, associated risk factors and outcome of patients infected with C. auris.
An overview of Candida auris in Iraq: the silent killer
2023, Acta Scientiarum - Biological SciencesEmergence of highly resistant Candida auris in the United Arab Emirates: a retrospective analysis of evolving national trends
2023, Frontiers in Public Health
© 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.